Zealand Pharma A/S (ZEAL) 2019年年度报告「NASDAQ」.pdf

1、Zealand Pharma Annual Report 2019Company reg.no.20045078Delivering on our commitment to patientsOn the coverCrosby was born with congenital hyperinsulinism.Read more page 18In consideration of our impact on the environment,the Zealand Pharma Annual Report will transition to electronic copy only.A li

2、mited number of printed copies will be made of the Annual Report 2019,and it will be the last publication produced in print.2Zealand Pharma Annual Report 20192Zealand Pharma Annual Report 2019ContentsChanging lives 4About Zealand Pharma 5Shareholder Letter 62019 Achievements and financial highlights

3、 8Consolidated Key Figures 102020 Outlook and objectives 11Transforming peptides 12Pipeline overview 14Dasiglucagon:Severe hypoglycemia 16Dasiglucagon:Congenital hyperinsulinism 18Dasiglucagon:Automated diabetes management 20Dasiglucagon:Hypoglycemia following bariatric surgery 21Glepaglutide and ZP

4、7570:Short bowel syndrome 22Pre-clinical projects 25Approaching commercialization 26 Engaging partnerships 28Corporate matters 31Corporate Governance 32Corporate Responsibility 35Our People 36Risk Management and Internal Control 38Financial Review 40Shareholder Information 43Board of Directors 45Cor

5、porate Management 47Financial statementsConsolidated financial statementsIncome statement 50Statement of comprehensive income 50Statement of financial position 51Statement of cash flows 52Statement of changes in equity 52Business overview 53Notes 54Financial statements of the parent companyIncome st

6、atement 88Statement of comprehensive income 88Statement of financial position 89Statement of cash flows 90Statement of changes in equity 90Notes 91Alternative performance measures for the group(non-audited)100Statement of the Board of Directors and Executive Management 101Independent auditors report